Large gap with delayed quotes
|
Last quote
04/27/2026
-
17:56:02
|
Bid
04/27/2026 -
17:57:19
|
Bid Volume |
Ask
04/27/2026 -
17:57:19
|
Ask Volume |
|---|---|---|---|---|
|
25.32
0.00
(
0.00% )
|
25.26
|
200 |
25.37
|
400 |
Analysis date: 24.04.2026
Global Evaluation
Negativ
Negativ
The stock is classified in the negative zone since 21.04.2026.
Interest
None
None
No stars since 21.04.2026.
Earnings Rev Trend
Negative
Negative
Compared to seven weeks ago, the analysts have lowered their earnings per share estimates. This negative trend began 10.03.2026 at a price of 28.26.
Evaluation
Strongly overvalued
Strongly overvalued
Based on its growth potential and our own criteria, we believe the share price is currently overvalued.
MT Tech Trend
Negative
Negative
The dividend-adjusted forty day technical trend is negative since 21.04.2026.
4wk Rel Perf
-19.97%
-19.97%
The four-week dividend-adjusted underperformance versus SP500 is 19.97%.
Sensibility
High
High
High, no change over 1 year.
Bear Market Factor
High
High
On average, the stock has a tendency to amplify the drops in the index by 1.67%.
Bad News Factor
Low
Low
When the stock's pressure is specific, the market sanction on average is 3.42%.
Mkt Cap in $bn
1.48
1.48
With a market capitalization <$2bn, AGIOS PHARMACEUTICALS is considered a small-cap stock.
G/PE Ratio
1.49
1.49
A ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) higher than 0.9 indicates that the stock's price presents a discount to growth of
LT P/E
-7.20
-7.20
The estimated PE is negative: the financial analysts' earnings estimates forecast a loss.
LT Growth
10.71%
10.71%
The annualized growth estimate is for the current year to 2028.
Avg. Nb analysts
9
9
Over the last seven weeks, an average of 9 analysts provided earnings per share estimates.
Dividend Yield
0.00%
0.00%
The company is not paying a dividend.
Beta
146
146
For 1% of index variation, the stock varies on average by 1.46%.
Correlation
0.28
0.28
Stock movements are strongly independent of index variations.
Value at Risk
10.98
10.98
The value at risk is estimated at USD 10.98. The risk is therefore 43.36%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
19.09.2014
19.09.2014